HDAC9 and myelodysplastic syndrome: HDAC inhibitors as a single agent or a part of combination regimes have been explored in other solid and hematological tumors, such as NSCLC, gastrointestinal carcinoma, malignant pleural mesothelioma, neuroblastoma, AML, MDS, and so on.514